Discussion | Using generic medications has been associated with higher adherence and improved clinical outcomes. 5 Yet, brandname medications are often prescribed when generic equivalents exist, leading to unnecessary costs. 6 The 23.1 percentage point generic prescribing rate increase in this study compares favorably with the 5.4 percentage point increase in prior work. 3 The opt-out rate for generic levothyroxine was 22.1% after the intervention, compared with less than 2% among other medications, likely reflecting physician recognition that generic and brand-name levothyroxine may differ in formulation. 4 This provides a real-world illustration of what has been a hypothesis in the health care context: that the effectiveness of defaults in changing behavior is appropriately mitigated in the setting of strongly held preferences. 2 Our results are limited to 1 health system and, in some settings, our intervention may be less effective than it appears because brand-name prescriptions are often converted to generics at pharmacies before dispensing. Nonetheless, our findings indicate that the manner that default options are designed and implemented has an important influence on their effectiveness for changing physician behavior.
Generic drugs are low-cost, therapeutically equivalent versions of brand-name drugs. Use of generic drugs increases patient adherence and improves health outcomes. 1 However, a 2009 survey of physicians showed that 23% disagreed that generic dr ugs were as effec tive as brand-name drugs and 50% reported quality concerns, leading more than one-quarter not to recommend generic drugs as first-line therapy. 2 Because generic drugs now make up more than 85% of prescriptions, 3 we reassessed physicians' perceptions and determined how professional or demographic characteristics predict physicians' support of generic drug prescribing.
Methods | From a master list of American Board of Internal Medicine diplomates, we randomly selected 300 clinically active internists and 900 specialists in endocrinology, hematology, and infectious diseases (52 excluded for lacking contact information). We emailed the survey link ($50 honoraria), with nonresponders receiving 2 reminders, a mailed version, and a final email reminder (the study was approved by Brigham and Women's Hospital Institutional Review Board with an authorization agreement from the US Food and Drug Administration Research Involving Human Subjects Committee). Consent was implied based on reading the survey goals and participating. Using 5-point Likert scales, we measured respondents' perceptions of generic drugs and how they last learned about a newly available generic drug.
Our first outcome variable was generic skepticism, defined as answering neutral or negative to whether generic drugs were as safe and effective as brand-name drugs, or answering neutral or positive to whether generic drugs cause more adverse effects. In sensitivity analyses, we excluded neutral responses. The second outcome variable was self-reported "brand-name-only" prescribing more than 5% of the time. 4 We assessed response variations among demographic and practice characteristics, using Pearson χ 2 test and 2-sample t tests. The Wilson method identified confidence intervals for proportions 5 and logistic regression estimated adjusted associations (Stata, version 13.1; StataCorp).
Results | Among 718 respondents (62.3% response rate), the mean (SD) age was 46 (10) years, 54% (374 of 687) were male, 61% (387 of 639) trained at US medical schools, and 58% (393 of 675) were white. Nonrespondents had a mean (SD) age of 49 (11) years, and 57% (293 of 510) were male.
Generic drugs were widely favored: 638 respondents (89% [95% CI, 86%-91%]) perceived them as effective and 653 (91% [95% CI, 89%-93%]) perceived them to be as safe as their brandname counterparts, while 523 (73% [95% CI, 70%-76%]) agreed that they do not cause more adverse effects and 500 (70% [95% CI, 66%-73%]) preferred prescribing generic over brandname drugs ( Table 1) .
Generic skeptics (32% of sample [227 of 718]) showed no significant variation in demographic or practice characteristics. Approximately half "sometimes," "rarely," or "never" knew when generic drugs became available, with 155 (22% [95% CI, 19%-25%]) last learning about generic availability from pharmaceutical representatives ( a All responses were measured on a 5-point Likert scale of "strongly agree," "somewhat agree," "neither agree nor disagree," "somewhat disagree," and "strongly disagree." b Denominators vary across questions due to missing data. c This question asked whether physicians believe that generics cause more adverse effects than brand-name drugs. Responses inverted for consistency of interpretation with the other questions in this Table. Approximately 35% reported brand-name-only prescribing more than 5% of the time, with higher rates among physicians who last learned about generic drugs from pharmaceutical representatives (51% After restricting the analytic data set to the 612 physicians with complete demographic and practice variables (except type) and adjusting for these variables, learning about availability of a generic drug from a pharmaceutical representative continued its positive association with higher brand-name-only presc ribing (47% vs 30%; P < .001), but not with generic skepticism (35% vs 30%; P = .26). Excluding neutral responses from the skepticism definition reduced the proportion to 15% (108 of 718) but affected none of the comparisons.
Discussion | These results suggest an overall shift in the perceptions of board-certified internal medicine physicians and certain specialists about generic drugs toward greater confidence in their quality and safety. Still, generic skepticism remains common, particularly among physicians who reported pharmaceutical sales representatives as sources of the last times they learned about generic drugs becoming available. While several tests of significance were conductedincreasing the likelihood that at least 1 significant result may be a false positive-our data suggest that limiting interactions with pharmaceutical marketing and directed educational outreach could help ensure that generic drug prescribing remains widespread for the benefit of patients and to help slow the rate of increase of health care costs. 
LESS IS MORE

Generic Medication Prescription Rates After Health System-Wide Redesign of Default Options Within the Electronic Health Record
The growing adoption of the electronic health record (EHR) brings new opportunities to improve physician decision making toward higher-value care. 1 Default options, or the conditions that are set into place unless an alternative is actively chosen, have been shown to influence decisions in many contexts. 2 However, the effectiveness of different w a y s o f i m p l e m e n t i n g defaults has not been systematically examined in health care, and many people may assume that changing defaults is a one size fits all intervention that will always have the same effect. 2 In prior work, changing the design of EHR medication display defaults for internal medicine physicians increased generic prescribing rates by 5.4 percentage points. 3 In that intervention, the process of searching for a brand-name medication changed from displaying a list of brand-name options followed by their generic equivalents to displaying only generic-equivalent options. To view brand names, a physician had to click on another tab. In November 2014, the University of Pennsylvania Health System implemented a different change in EHR defaults among all specialties across the entire health system. Instead of changing EHR display defaults, an opt-out checkbox labeled "dispense as written" was added to the prescription screen, and if left unchecked the generic-equivalent medication was prescribed. The objective of this study was to evaluate the effect of this intervention on physician prescribing behaviors.
Methods | Monthly prescription data from all University of Pennsylvania Health System outpatient clinics between January 2014 and June 2015 were obtained using Clarity, an EPIC reporting database. We included new prescriptions for oral medications often prescribed for 10 common medical conditions: acid reflux, anxiety and/or insomnia, bacterial infection, depression, diabetes, hyperlipidemia, hypertension and/or congestive heart failure, hypothyroid, pain, and seizure. Medications without an available generic-equivalent drug and combination pills were excluded. The University of Pennsylvania institutional review board deemed the study exempt.
Generic prescribing rates were compared between the preintervention period (January 2014 to October 2014) and the postintervention period (December 2014 to June 2015) using χ 2 tests. A difference-in-differences approach was used to test whether levothyroxine, a medication known to often have different levels of thyroid hormone than its brand-name formulation, 4 had a different change in trend than other medications with similar baseline generic prescribing rates. Hypothesis tests were 2-sided with a significance level of P < .05. Analyses were conducted using Stata Version 12 (StataCorp).
Results | The overall generic prescribing rate increased significantly from 75.3% (611 068 of 811 561 prescriptions) during the 10-month preintervention period to 98.4% (644 587 of 655 011 prescriptions) during the 7-month postintervention period (P < .001) ( Figure) . Compared with other medications with similar baseline generic prescribing rates, there was less of an increase for levothyroxine representing a greater proportion of opt-outs (adjusted difference-in-difference, −15.6 percentage points; 95% CI, −16.4 to −14.8; P < .001) (Table) . 
Association Between the Centers for Medicare and Medicaid Services Hospital Star Rating and Patient Outcomes
In an effort to help patients choose hospitals based on quality, the Centers for Medicare and Medicaid Services (CMS) recently introduced a 5-star hospital rating system. This rating depends solely on patient experience based on the Hospital Consumer Assessment of Healthcare Providers and Systems, and currently, it does not include measures of quality of care or patients' health outcomes. Whether hospital stars are associated with better outcomes is unclear, and critics worry that the star rating system may mislead patients into thinking that 5-star hospitals are superior in quality. [1] [2] [3] [4] Therefore, we investigated whether hospitals with more stars have lower riskadjusted 30-day mortality and readmissions than hospitals with less stars.
Methods | The study was approved by the institutional review board at the Harvard T. H. Chan School of Public Health. We linked the October 2015 Hospital Compare data on hospital star ratings 5 with the American Hospital Association annual survey database. We evaluated the characteristics of hospitals by a Data represent linear probability regression model estimate for change in the trend of levothyroxine from the preintervention period to the postintervention period relative to the change in trend of all other medications (Overall) presented over the same time period. b Refers to the aggregate generic prescription rates for the medications listed above.
